创新药强复苏！CRO二波行情已启动？这波机会别错过！

Group 1 - The domestic pharmaceutical industry is expected to experience a significant turning point in 2025, with the innovative drug sector emerging from an adjustment period to achieve a strong recovery, becoming the core growth engine of the pharmaceutical sector [1] - In the secondary capital market, the CRO sector showed a clear net inflow of funds in January 2026, indicating a strong trend reversal signal, supported by the recovery of industry prosperity and improvement in fundamentals [1][3] - The investment and financing market is recovering, with the scale of BD going overseas reaching a historical high, alongside improvements in IND application and review efficiency, leading to a comprehensive release of demand in the clinical CRO industry [3][6] Group 2 - In the first three quarters of 2025, the financing amount in the primary healthcare market reached 79.53 billion yuan, a year-on-year increase of 22.4%, indicating a bottom reversal characteristic of "funds warming up first, projects following" [6] - The capital allocation logic has shifted from "early and small investments" to "investing in clinical and certainty," with a significant increase in the proportion of later-stage financing, which directly drives the demand for CRO and SMO services [6][7] - The total transaction amount for innovative drug BD overseas reached 135.7 billion USD in 2025, with upfront payments of 7 billion USD, marking a historical high and establishing China as the second-largest source of projects for multinational pharmaceutical companies [7] Group 3 - The number of IND applications accepted by the CDE in 2025 reached 1,878, a year-on-year increase of 13.34%, with class 1 innovative drug IND applications accounting for over 70%, indicating a shift in R&D resources towards quality [8][9] - The approval rate for class 1 innovative drug INDs reached 96.53%, and the NDA approval rate was 86.87%, reflecting significant improvements in review efficiency and approval rates [12] - The global regulatory environment is shifting towards efficiency, with the FDA focusing on enhancing R&D and review efficiency, which is expected to accelerate the demand for clinical CRO services [12][13] Group 4 - The comprehensive recovery of the innovative drug industry in 2025 presents historic development opportunities for the CRO industry, with multiple favorable factors driving the industry's prosperity [14] - It is recommended to focus on leading clinical CRO companies with digital platforms, robust compliance systems, and scale advantages, as they are expected to benefit significantly from the release of industry demand [14]